Discovery of SCY45, a Natural Small-Molecule MDM2-p53 Interaction Inhibitor

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• The MDM2-p53 interaction is a crucial target for developing novel anticancer drugs.
• Inhibiting this interaction can restore tumor suppressor functions of p53.
• Small molecules offer a promising avenue for targeting protein-protein interactions.

Purpose of the Study:

• To identify and characterize novel inhibitors of the MDM2-p53 interaction.
• To evaluate the anticancer potential of a natural small-molecule, SCY45.
• To investigate the efficacy of SCY45 in cancer cells with varying MDM2 gene copy numbers.

Main Methods:

• Fluorescence polarization assays were used to measure the inhibition of MDM2-p53 interaction.
• Molecular modeling was employed to understand the binding mode of SCY45.
• Cell viability assays were performed on cancer cell lines with different MDM2 gene amplification levels.

Main Results:

• SCY45 was identified as a potent inhibitor of the MDM2-p53 interaction with an IC50 of 4.93 μm.
• Molecular modeling revealed SCY45 binds to the p53-binding pocket of MDM2 similarly to nutlin-3a.
• SCY45 demonstrated reduced cancer cell viability, with higher efficacy in cells exhibiting MDM2 gene amplification (e.g., SJSA-1 cells).

Conclusions:

• SCY45 is a promising natural small-molecule inhibitor of the MDM2-p53 interaction.
• Its mechanism involves binding to the MDM2 p53-binding pocket.
• SCY45 exhibits anticancer activity, particularly against cancers with MDM2 gene amplification, warranting further investigation.